Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Analysts at Stifel Canada issued their Q1 2025 EPS estimates for shares of Cipher Pharmaceuticals in a research report issued on Monday, March 24th. Stifel Canada analyst J. Keywood forecasts that the company will earn $0.21 per share for the quarter. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.29 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals' Q2 2025 earnings at $0.24 EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.26 EPS and FY2025 earnings at $0.99 EPS.
Cipher Pharmaceuticals Price Performance
Shares of CPH stock traded down C$0.41 during trading on Wednesday, hitting C$12.57. The company had a trading volume of 22,598 shares, compared to its average volume of 35,882. Cipher Pharmaceuticals has a 52 week low of C$7.90 and a 52 week high of C$19.69. The stock has a market capitalization of C$225.67 million, a price-to-earnings ratio of 13.88 and a beta of 1.20. The company has a quick ratio of 2.67, a current ratio of 2.00 and a debt-to-equity ratio of 41.22. The stock's 50-day moving average is C$12.78 and its two-hundred day moving average is C$14.29.
Insider Transactions at Cipher Pharmaceuticals
In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin sold 3,500 shares of Cipher Pharmaceuticals stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of C$13.49, for a total value of C$47,215.00. Insiders own 42.00% of the company's stock.
About Cipher Pharmaceuticals
(
Get Free Report)
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
See Also
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
